Araris Logo
Araris’ platform technology links highly potent cytotoxic agents to off-the-shelf antibodies, thus forming Antibody-Drug-Conjugates (ADCs). Up to now, the use of ADCs was limited due to challenges in manufacturing, stability, and bioavailability leading to toxicity, lack of efficacy, and drug resistance. Araris’ proprietary linker technology and conjugation method address these major shortcomings. Its approach has not only the potential to drastically simplify and accelerate ADC development & manufacturing, but also to improve safety and tolerability in patients.